SOPHiA GENETICS

Optimism is always a competitive advantage. That is how Poppy Gustafsson sees the future of technology. Poppy co-founded Darktrace, the AI-powered cybersecurity company, led it as CEO to a $5.3 billion exit, and then became the UK’s Minister for Investment. I sat down with her for Episode 16 of Decoded to talk about leading at scale, working inside government, and where Europe goes next in AI. In this episode, you will hear: - Why a chartered accountant’s most valuable skill turned out not to be the numbers - The headcount at which a CEO has to change how they comfmunicate - What surprised Poppy most about government - Why trust could be Europe’s opening in the AI race - The difference between AI that is available to all and AI that is accessible to all - What Blade Runner imagined, what it missed, and what it tells her about the future for her two daughters. I hope you enjoy the conversation as much as I did. Listen to the full episode on Spotify https://lnkd.in/ec9CRq5P

🚀 Access to liquid biopsy is only the beginning. What comes next? The next generation of oncology biomarkers is becoming increasingly complex, creating new challenges for assay development, validation, and patient identification. Join our forum, The Liquid Biopsy Movement: From Access to Action, where oncology KOLs, pharma and diagnostic leaders will explore: 🎯 What routine adoption of liquid biopsy at scale looks like in practice ✨ How the lessons learned from MSK-ACCESS® deployment can help expand access to emerging biomarkers 📅 October 22 | Madrid, Spain We look forward to seeing you there! 👉🏼 Secure your spot

🧬 The liquid biopsy movement is entering its next chapter. What began as a pioneering collaboration between SOPHiA GENETICS and Memorial Sloan Kettering Cancer Center (MSK) to expand access to liquid biopsy is now driving a broader conversation: how is this access being turned into action? Join pharma, biotech, and oncology leaders at the SOPHiA GENETICS Global Precision Medicine Forum to reflect on what it takes to scale liquid biopsy and bring the next generation of biomarkers closer to clinical reality. 📅 October 22 | Madrid, Spain 👉🏼 Register your interest now

✨ The Liquid Biopsy Movement: From Access to Action As oncology biomarkers become more complex, diagnostic development, validation, and access need to keep pace with therapeutic innovation. Join pharma and diagnostic leaders at the SOPHiA GENETICS Global Precision Medicine Forum to explore how ecosystem partnerships can help bring new assays for challenging biomarkers closer to patients. 📅 October 22 | Madrid, Spain 👉🏼 Be part of the conversation and register today

My new Decoded episode is live. 130 Years, 4 Generations, 1 Rule: Patients Before Shareholders I sat down with André Hoffmann, Vice-Chair of Roche and the fourth generation of the Hoffmann family to lead the company since 1896. We discussed how genomics and AI are transforming drug discovery, what organizational structures enable long-term innovation, and why the way we measure success in business needs to evolve. In this episode, we cover: - How genomics is dismantling the blockbuster playbook - Where AI fits into modern drug discovery and development - The talent, infrastructure, and mindset shifts this requires - Why 130 years of family ownership is a business superpower - How new accounting systems can measure what we actually take from nature - What real success looks like (hint: it's not in your bank account) André walks through how Roche is adapting to precision medicine, the strategic advantage of being able to invest in 15-year development cycles, and his thinking on sustainable business practices. He shares insights on ownership models, innovation timelines, and how companies measure impact. This is a conversation about the intersection of technology, business structure, and purpose in modern pharma. Listen to the full episode https://lnkd.in/eepqMpca

🚀 Access to liquid biopsy is only the beginning. What comes next? The SOPHiA GENETICS Global Precision Medicine Forum brings together oncology KOLs, clinicians and pharma leaders together to explore what it takes to make liquid biopsy a reality in clinical practice, and how the lessons learned can extend to emerging and complex biomarkers. 🧬 From decentralized testing to real-world implementation ✨ From biomarker complexity to actionable insights 🏥 From innovation to patient access 📅 October 22 | Madrid, Spain We look forward to seeing you there! 👉🏼 Secure your spot